IP Library Patent Application 11987946
Patent Application
App. No. 11/987,946

Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/987,946
Abstract

Provided is a method for suppressing carcinogenesis, treating cancer, or mitigating adverse reactions of anticancer agents, with low prevalence of adverse reactions by administering an effective amount of a reduced coenzyme Q as an active ingredient. In the method, the reduced coenzyme Q can be administered in the form of pharmaceuticals, cosmeceutical, cosmetics, foods such as functional foods (supplements, health aid foods, nutritional supplementary foods, nutrient-fortified foods, nutrient-adjusted foods, health beverages, foods for specified health uses, foods with nutrient function claims), animal drugs, animal feeds, or animal foods.

Claims (11)

1 . A method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents, comprising administering an effective amount of a reduced coenzyme Q represented by the formula (1):

(wherein n represents an integer of 1 to 12) to a subject of administration.

2 . The method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions according to claim 1 , wherein the reduced coenzyme Q is reduced coenzyme Q 10 .

3 . The method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions according to claim 1 above, wherein the reduced coenzyme Q is administered in a daily dose of 1 mg to 3000 mg.

4 . The method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions according to claim 1 , wherein the reduced coenzyme Q is co-administered with an anticancer agent that is not a reduced coenzyme Q.

5 . The method according to claim 1 , wherein the reduced coenzyme Q is administered in a composition containing 0.001 to 99.9% by weight of the reduced coenzyme Q.

6 . The method according to claim 1 , wherein the reduced coenzyme Q is administered as a pharmaceutical, a cosmeceutical or a cosmetic.

7 . The method according to claim 1 , wherein the reduced coenzyme Q is administered as a food or a beverage.

8 . The method according to claim 1 , wherein the reduced coenzyme Q is administered as an animal drug, an animal feed or an animal food.

9 . A cancer therapeutic agent or carcinogenesis suppressant comprising a combination of a reduced coenzyme Q represented by the formula (1):

(wherein n represents an integer of 1 to 12) and an anticancer agent that is not a reduced coenzyme Q.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 12, 2013
From: KANEKA CORPORATION
To: KANEKA CORPORATION
Reel/Frame 031207/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2008
From: FUJII, TOSHIHIDE; KATO, MASANORI; SAKAMOTO, HIROKAZU; SHINAGAWA, YOSHIYUKI; KITANO, MITSUAKI; HOSOE, KAZUNORI
To: KANEKA CORPORATION
Reel/Frame 020536/0659 →